Stimulant use disorder (StUD) is the fastest-growing driver of overdose deaths in the United States, yet unlike opioid use disorder (OUD), there are no FDA-approved medications. Contingency management (CM) is the most effective behavioral treatment for StUD, but uptake has been slow and long-term outcomes—including mortality—have been understudied. This presentation describes a cohort study using linked electronic health records and death records from the Veterans Health Administration (VHA), the largest integrated health system in the U.S., examining whether patients with StUD who received CM had reduced all-cause mortality compared to matched controls who did not. Results demonstrated that CM was associated with a 41% reduction in mortality over one year (aHR=0.59, 95% CI=0.36, 0.95), comparable in magnitude to the mortality benefit of buprenorphine for OUD. The session will cover the study design, findings, clinical implications, and current landscape of CM implementation including policy barriers and ongoing state Medicaid demonstrations.
At the conclusion of this seminar, attendees should be able to:
Continuing Medical Education (CME) Credits Available
Participants in this program may earn the following CME credits:
✔ 1 AOA Category 1-A Credit✔ 1 AMA PRA Category 1 Credit™✔ 1 AAPA Category 1 CME Credit ✔ 1 Nurses CNE Credit
Earn valuable continuing education credits while enhancing your professional knowledge!